The isocitrate dehydrogenase (IDH) gene is recurrently mutated in adult diffuse gliomas. IDH-mutant gliomas are categorized into oligodendrogliomas and astrocytomas, each with unique pathological features. Here, we use single-nucleus RNA and ATAC sequencing to compare the molecular heterogeneity of these glioma subtypes. In addition to astrocyte-like, oligodendrocyte progenitor-like, and cycling tumor subpopulations, a tumor population enriched for ribosomal genes and translation elongation factors is primarily present in oligodendrogliomas. Longitudinal analysis of astrocytomas indicates that the proportion of tumor subpopulations remains stable in recurrent tumors. Analysis of tumor-associated microglia/macrophages (TAMs) reveals signific...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
BACKGROUND: To investigate the dynamics of inter- and intratumoral molecular alterations during tumo...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
<div><h3>Background</h3><p>To investigate the dynamics of inter- and intratumoral molecular alterati...
Background: To investigate the dynamics of inter- and intratumoral molecular alterations during tumo...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the ...
BACKGROUND: To investigate the dynamics of inter- and intratumoral molecular alterations during tumo...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
<div><h3>Background</h3><p>To investigate the dynamics of inter- and intratumoral molecular alterati...
Background: To investigate the dynamics of inter- and intratumoral molecular alterations during tumo...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...
The factors driving therapy resistance in diffuse glioma remain poorly understood. To identify treat...